

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Compare the response to treatment in patients with newly diagnosed chronic hepatitis C (genotype I ) and patients without any response to previous treatments , with combination of sofosbuvir-daklatsvir

#### Protocol summary

##### Summary

(1) The aim of this study was to compare the response to treatment in patients with newly diagnosed administration drug sofosbuvir chronic hepatitis C genotype and patients with a previous treatment failure. (2) In this study, an experimental clinical trial carried out, (3) patients chronic hepatitis C infections with genotype one who refer Gastroenterology Clinics of Medical Sciences, 25 of people who ribavirin and interferon already had been in the first group and The 25 people who were newly diagnosed and had no previous treatment were selected in the second group. The two groups were matched for age, sex and diseases. (4) Inclusion criteria for this study, patients with HCV genotype HCV RNA in a headline above or positive and people who have detectable HCV RNA titers after previous treatment failure and relapse. Exclusion criteria from the study, those who sofosbuvir therapy to stop for any reason, People infected with virus (HIV) simultaneously, chronic liver disease who are reason other than HCV. (5) Patients with drug therapy, Sofosbuvir daily oral dose of 400 mg and a dose of 60 mg daily Daklatsvir oral pharmaceutical composition sofosbuvir for 12 weeks and (6) The results of treatment using HCV RNA at weeks 24,12,4 title will be monitored to determine response to therapy in each patient and compared between the two groups.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201702016388N7**  
Registration date: **2017-04-08, 1396/01/19**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2017-04-08, 1396/01/19

##### Registrant information

###### Name

Mohamadhossein Somi

###### Name of organization / entity

Tabriz University of Medical Science

###### Country

Iran (Islamic Republic of)

###### Phone

+98 41 1336 7499

###### Email address

somimh@tbzmed.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

Vice Chancellor for Research Tabriz University of Medical Science

##### Expected recruitment start date

2016-11-12, 1395/08/22

##### Expected recruitment end date

2017-05-22, 1396/03/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Compare the response to treatment in patients with newly diagnosed chronic hepatitis C (genotype I ) and patients without any response to previous treatments , with combination of sofosbuvir-daklatsvir

##### Public title

Response to treatment in patients with chronic hepatitis C genotype and drug sovodak newly diagnosed patients with previous treatment failure

2016-11-09, 1395/08/19

**Ethics committee reference number**  
IR.tbzmed.ac.ir.1395.871

### **Purpose**

Treatment

### **Inclusion/Exclusion criteria**

Inclusion criteria: People with HCV genotype HCV RNA in a headline above or positive: People who have detectable HCV RNA titers after previous treatment failure and relapse patients. Exclusion criteria: People who sovodak therapy to stop for any reason: People infected with virus (HIV) concurrently: There is no reason other than HCV patients with chronic hepatitis: People with hepatitis B concurrently: People who have undergone liver transplantation recently: People who have low life expectancy: There is no assurance that the cut intravenous drug users inject drugs: Patients who received Amiodarone in the last 6 months: Women who are pregnant or plan to become pregnant or are breastfeeding: Those who have allergies to Lactose (sovodak with Lactose).

### **Age**

No age limit

### **Gender**

Both

### **Phase**

2

### **Groups that have been masked**

No information

### **Sample size**

Target sample size: 50

### **Randomization (investigator's opinion)**

N/A

### **Randomization description**

### **Blinding (investigator's opinion)**

Not blinded

### **Blinding description**

### **Placebo**

Not used

### **Assignment**

Parallel

### **Other design features**

## **Secondary Ids**

empty

## **Ethics committees**

### **1**

#### **Ethics committee**

##### **Name of ethics committee**

Ethics Committee of Tabriz University of Medical Sciences

##### **Street address**

Central bulding of medical science university, St. Goltasht, St. Azadi ,Tabriz

##### **City**

Tabriz

##### **Postal code**

##### **Approval date**

## **Health conditions studied**

### **1**

#### **Description of health condition studied**

Chronic Hepatitis C

#### **ICD-10 code**

B18.2

#### **ICD-10 code description**

Chronic viral hepatitis C

## **Primary outcomes**

### **1**

#### **Description**

Hepatitis C RNA

#### **Timepoint**

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment

#### **Method of measurement**

Test

## **Secondary outcomes**

### **1**

#### **Description**

Liver Echogenicity

#### **Timepoint**

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment

#### **Method of measurement**

paraclinical tests

### **2**

#### **Description**

Albumin

#### **Timepoint**

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment

#### **Method of measurement**

Test

### **3**

#### **Description**

Portal vein diameter

#### **Timepoint**

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment

#### **Method of measurement**

Sonography

### **4**

#### **Description**

Splenic vein diameter

**Timepoint**

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment

**Method of measurement**

Sonography

**5**

**Description**

Spleen size

**Timepoint**

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment

**Method of measurement**

Sonography

**6**

**Description**

INR

**Timepoint**

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment

**Method of measurement**

Test

**Intervention groups**

**1**

**Description**

In the intervention group, patients with hepatitis C who were treated with other drugs and were facing defeat, Drug treatment, Sofosbuvir daily at a dose of 400 mg daily oral doses of 60 mg Daklinza oral pharmaceutical composition in a single pill called sovodak will receive for 12 weeks.

**Category**

Treatment - Drugs

**2**

**Description**

In the control group of patients with hepatitis C who have not previously undergone any treatment, Drug treatment, Sofosbuvir daily at a dose of 400 mg daily oral doses of 60 mg Daklinza oral pharmaceutical composition in a single pill called sovodak will receive for 12 weeks.

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Tabriz University of Medical Sciences, Imam Reza Hospital

**Full name of responsible person**

Dr. Hosein Mehdipour

**Street address**

Endoscopy ward, First floor, Imam Reza Hospital, St. Golgasht, St.Azadi, Tabriz, East Azarbaijan

**City**

Tabriz

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Vice Chancellor for Research of Tabriz University of Medical Sciences

**Full name of responsible person**

Dr. Mohammad Reza Rashidi

**Street address**

Vice chancellor for Research of Tabriz University of Medical Sciences, Tabriz University of Medical Sciences, Golgasht Street, Tabriz

**City**

Tabriz

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice Chancellor for Research of Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

empty

**Domestic or foreign origin**

empty

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

empty

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr. Mohammad Hosein Somi

**Position**

Gastroentology and hepatology/ Professor

**Other areas of specialty/work**

**Street address**

Endoscopy ward, First floor, Imam Reza Hospital, St. Golgasht, St.Azadi, Tabriz

**City**

Tabriz

**Postal code**

**Phone**

+98 41333347554

**Fax**

**Email**

somimh@tbzmed.ac.ir

**Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr. Mohammad Hosein Somi

**Position**

Gastroenterology and hepatology/ Professor

**Other areas of specialty/work****Street address**

Endoscopy ward, First floor, Imam Reza Hospital, St. Goltasht, St.Azadi, Tabriz

**City**

Tabriz

**Postal code****Phone**

+98 41333347554

**Fax****Email**

somimh@tbzmed.ac.ir

**Web page address****Person responsible for updating data****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr. Hosein Mehdipour

**Position**

Gastroenterology and hepatology assistant

**Other areas of specialty/work****Street address**

Endoscopy ward, First floor, Imam Reza Hospital, St. Goltasht, St.Azadi, Tabriz, East Azarbaijan

**City**

Tabriz

**Postal code****Phone**

+98 41333347554

**Fax****Email**

hosein.mehdipour@gmail.com

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*